KRAS and familial pancreatic carcinoma: Even, the presence of KRAS mutation prognosticates shorter disease-free survival in patients with localized tumor.14 Recently, it was observed that activation of c-Myc is enough to convert indolent pancreatic intraepithelial neoplasm into pancreatic cancer in mice.15 Suppression of c-Myc in resistant pancreatic cancer could improve response to ordinary chemotherapeutic agents in preclinical studies.10